141 – 150 of 306
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Dramatic differences in susceptibility to L-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion
(
- Contribution to journal › Article
-
Mark
Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease : An open-label prospective observational study of effectiveness, tolerability and healthcare costs
(
- Contribution to journal › Article
-
Mark
Platelet-derived growth factor-BB has neurorestorative effects and modulates the pericyte response in a partial 6-hydroxydopamine lesion mouse model of Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of α-synuclein
2016) In Proceedings of the National Academy of Sciences of the United States of America 113(26). p.7065-7070(
- Contribution to journal › Article
-
Mark
Duration of disease does not equally influence all aspects of quality of life in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression
(
- Contribution to journal › Article
-
Mark
Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis
(
- Contribution to journal › Scientific review
- 2015
-
Mark
Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease - Clinical practice recommendations
(
- Contribution to journal › Scientific review
-
Mark
EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study
(
- Contribution to journal › Article